The Library
Every peptide, graded on its evidence
52 compounds across 9 categories — mechanism, evidence, protocols, interactions, and monitoring for each.
10 compounds
Semaglutide
Ozempic · Wegovy
The most rigorously studied GLP-1 receptor agonist for weight and glycemic control.
Tirzepatide
Mounjaro · Zepbound
Dual GIP/GLP-1 agonist producing the largest weight reduction of any approved agent to date.
Retatrutide
LY3437943 · Triple-G
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously.
Liraglutide
Saxenda · Victoza
Daily GLP-1 agonist — the predecessor to semaglutide, still useful where fine dose control matters.
Cagrilintide
AM833
Long-acting amylin analogue that targets satiety through a pathway independent of GLP-1.
AOD-9604
Anti-Obesity Drug 9604 · hGH fragment analogue
A growth hormone fragment marketed for fat loss that failed to beat placebo in human trials.
HGH Fragment 176-191
Frag 176-191 · Lipolytic fragment
The unmodified GH fragment AOD-9604 was derived from — same lipolytic claim, weaker evidence.
5-Amino-1MQ
5-Amino-1-methylquinolinium
Oral NNMT inhibitor studied in rodents for fat-cell metabolism — no human trials exist.
SLU-PP-332
ERR agonist
An experimental 'exercise mimetic' that activates estrogen-related receptors — animal data only.
AICAR
Acadesine · AICA riboside
An AMPK-activating 'exercise mimetic' with animal endurance data — and a WADA ban.
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Not sure where to begin? Take the goal assessment and let your answers narrow it down.